Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study

Pol S, Thompson A, Collins M, Venier E, Cotte L, Laguno Centeno M, et al. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study. Hepatology, May 20, 2024. | DOI: 10.1097/HEP.0000000000000923 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες

Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

Grishma H, Bettina H, Chien-Hung C et al, on behalf of the RETRACT-B study group. Am J Gastroenterol, 2024 DOI: 10.14309/ajg.0000000000002759 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες

Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial

Wang B, Zhou J, Wu X, Sun Y, Li L, Li P, et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial. Am J Gastroenterol. 2024 Apr 1;119(4):700-711. doi: 10.14309/ajg.0000000000002569. Epub 2023 Nov 6. PMID: 37929952 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες

A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis

Marta Tonon, Roberta D’Ambrosio, Valeria Calvino, Salvatore Piano, Pietro Lampertico, Paolo Angeli https://doi.org/10.1016/j.jhep.2023.12.005 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες

Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

Semmler G, Alonso lópez S, Pons M, Lens S, Dajti E, Griemsmann M, et al. Published: March 21, 2024, Journal of Hepatology DOI: https://doi.org/10.1016/j.jhep.2024.03.015 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες

Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol- related liver disease

Katrine Holtz Thorhauge , Georg Semmler, Stine Johansen, Katrine Prier Lindvig, Maria Kjærgaard, Johanne Kragh Hansen, Nikolaj Torp, Camilla Dalby Hansen, Peter Andersen, MSc., Benedikt Silvester Hofer, M.D., Wenyi Gu, M.D., Mads Israelsen, PhD., Mattias Mandorfer, Ass. Prof., Thomas Reiberger, Prof., Jonel Trebicka, Prof., Maja Thiele, Prof., Aleksander Krag Πατώντας ΕΔΩ μπορείτε να δείτε την…

Λεπτομέρειες

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Stephen A Harrison, MD, Juan P Frias, MD, et al, for the HARMONY Study Group Lancet Gastroenterol Hepatol 2023, DOI:https://doi.org/10.1016/S2468-1253(23)00272-8 Πατώντας ΕΔΩ μπορείτε να δείτε την περίληψη του άρθρου

Λεπτομέρειες